Renal

  • CKD, Post On PCABS Renal Function
  • CKD, Post On PCABS Renal Protection Agent
  • Renal Biomarker
  • End-Stage Kidney Disease
  • Microalbuminuria, Hypertension, Type 2 Diabetes
  • Hyperuricemia, Renal Impairment, Gout
  • Hypertension, Proteinuria
  • Proteinuria, Hypertension, Type 2 Diabetes
  • Nephropathy, Hypertension, Type 2 Diabetes
  • CKD, Anemia
  • CKD without dialysis, Anemia
  • CKD, Proteinuria, Type 2 Diabetes
  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  • Secondary Hyperparathyroidism
  • Diabetic nephropathy

Integrium’s Metabolic Clinical Trial Experience

Renal

Overall Renal Experience
Study Phase Indication # Patients # Sites Location
0 CKD, Post On PCABS Renal Function 223 5 US, Brazil
I CKD, Post On PCABS Renal Protection Agent 30 1 US
II Renal Biomarker 32 6 US
II End-Stage Kidney Disease 79 14 US
II CKD, Post On PCABS Renal Protection Agent 310 25 US
II Microalbuminuria, Hypertension, Type 2 Diabetes 420 90 US
II Hyperuricemia, Renal Impairment, Gout 240 50 US
III Hypertension, Proteinuria 250 20 US
III Post On PCABS 2990 150 N. America, Europe
II Proteinuria, Hypertension, Type 2 Diabetes 210 20 US
IV Nephropathy, Hypertension, Type 2 Diabetes 856 124 US, S. America, S. Africa, Europe
II Proteinuria, Hypertension 50 4 US
II CKD, Anemia 114 19 US
II CKD, Anemia 20 2 US
IV Microalbuminuria, Hypertension, Type 2 Diabetes 400 90 N. America, Europe, S. Africa
II CKD without dialysis, Anemia 134 23 US
I CKD 63 5 US
II CKD, Proteinuria, Type 2 Diabetes 160 45 US
IIIb Autosomal Dominant Polycystic Kidney Disease (ADPKD) 2100 236 Europe, N. America, S. America
IIa Secondary Hyperparathyroidism 12 1 US
IIb Secondary Hyperparathyroidism 60 15 US
II Diabetic nephropathy 170 40 US